A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Clinical trial NCT05013905 · COMPLETED
Trial details
- NCT number
- NCT05013905
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-28
- Primary completion
- 2022-09-23
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.